Is The Stock Worthy? – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

Asian stocks were mixed in trading thinned by year-end holidays. Japanese benchmarks traded near the highest levels since the early 1990s, while China’s currency reached its strongest since September.

U.S. equity-index futures opened little changed in their first trading this week. Australia and Hong Kong markets remain shut Tuesday, with most of the rest of Asia back online. Shareholders had little reaction to Japanese data showing a drop in unemployment and slight acceleration in inflation. Traders are also digesting signals from China that authorities will accept some slowdown in growth as they seek to reduce financial risks.

The euro was trading little changed against the dollar, and at similar levels to the end of last week, after briefly sliding on Monday. Dramatic moves have occurred in recent years in the currency and other markets at times of low liquidity, when automated trading programs can sometimes be a contributing factor. Read more here about flash crashes in currencies.

Bitcoin steadied at around $14,000, after declining for most of the past week since reaching a record high above $19,000. The tumble had coincided with several warnings from financial authorities about elevated risk in holding digital coins.

Oil was trading above $58 a barrel, while commodities traded in China ticked lower on inventory-buildup concerns. (Source: Bloomberg)

Top Pick for Tuesday: Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) has grabbed attention from the analysts when it experienced a change of -2.27% in the last trading session to close at $1.72. A total of 128,573 shares exchanged hands during the intra-day trade contrast with its average trading volume of 756.65K shares, while its relative volume stands at 0.17. Relative volume is the comparison of current volume to average volume for the same time of day, and it’s displayed as a ratio. If RVOL is less than 1 it is not In Play on this trading day and Investors may decide not to trade it.  If RVOL is above 2 it is In Play and this is more evidence Investors ought to be in the name.  When stocks are *very* In Play one can see a RVOL of 5 and above.  The higher the RVOL the more In Play the stock is.

Day traders strive to make money by exploiting minute price movements in individual assets (usually stocks, though currencies, futures, and options are traded as well), usually leveraging large amounts of capital to do so, therefore they trade on Stocks in Play. In Play Stocks are volatile enough to produce good risk and reward trading opportunities for both bull and bear traders intraday. Most company stocks have very little volatility. They generally move extremely slowly and they only produce big price swings when the company produces good or bad trading results, which may only happen a couple of times a year at best.

In deciding what to focus on – in a stock, say – a typical day trader looks for three things: liquidity, volatility and trading volume. Liquidity allows an investor to enter and exit a stock at a good price (i.e. tight spreads, or the difference between the bid and ask price of a stock, and low slippage, or the difference between the predictable price of a trade and the actual price). If a stock does not have good liquidity then it may take some time before a broker is able to negotiate a deal to buy or sell a stock and the broker may not be able to get the sell or buy price that the trader is looking for. This is a problem for day traders and it could mean the difference between a profitable and non-profitable trade.

Traders have different rules for what constitutes liquidity and a good guide is the volume of trades and volume of shares that are traded each day. 100,000 shares traded per day would be a minimum for most traders and some require 1,000,000.

Trading volume is a gauge of how many times a stock is bought and sold in a given time period (most commonly, within a day of trading, known as the average daily trading volume – ADTV). A high degree of volume indicates a lot of interest in a stock. Often, a boost in the volume of a stock is a harbinger of a price jump, either up or down.

Volatility is simply a measure of the predictable daily price range—the range in which a day trader operates. More volatility means greater profit or loss. After a recent check, Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) stock is found to be 4.78% volatile for the week, while 8.65% volatility is recorded for the month.

Technical’s Snapshot:

The stock has a market cap of $21.00M and the number of outstanding shares has been calculated 12.21M. Based on a recent bid, its distance from 20 days simple moving average is -6.76%, and its distance from 50 days simple moving average is -4.28% while it has a distance of -43.51% from the 200 days simple moving average. The company’s distance from 52-week high price is -84.22% and the current price is 14.95% away from 52-week low price. The company has Relative Strength Index (RSI 14) of 44.70 together with Average True Range (ATR 14) of 0.14.

Stock’s Valuation:

Past 5 years growth of CYCC observed at -10.40%, and for the next five years the analysts that follow this company is expecting its growth at N/A. The stock’s price to sales ratio for trailing twelve months is 70.00 and price to book ratio for the most recent quarter is 0.72, whereas price to cash per share for the most recent quarter are 0.81. Its quick ratio for the most recent quarter is 6.50. Analysts mean recommendation for the stock is 2.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

Disclaimer: Any news, report, research, and analysis published on are only for information purposes. Alpha Beta Stock (ABS) makes sure to keep the information up to date and correct, but we didn’t suggest or recommend buying or selling of any financial instrument unless that information is subsequently confirmed on your own. Information in this release is fact checked and produced by competent editors of Alpha Beta Stock; however, human error can exist.

Eddie A. New focuses on breaking news stories and ensuring we offer timely reporting on some of the most recent stories released through market wires about Healthcare Sector companies. He has formerly spent over 5 years as a trader in U.S. Stock Market and is now semi-stepped down. He works on a full time basis for specializing in quicker moving active shares with a short term view on investment opportunities and trends.